6Wolfm AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trim of whole abdominal irradiation (WAI) vs. sisplatin - ifosfamide and meana ( CIM ) as post - surgi- cal therapy in stage I - IV Gyneeol Oneo1,2007,107 ( 2 ) : 177 - 185 (CS) of the uterus[J].
8Nemani D, Mitra N, Guo M. Assessing the effects of lymphadenecto- my and radiation therapy in patients with uterine carcinosarcoma:a SEER analysis [ J ]. Gynecol 0ncol,2008,111 ( 1 ) : 82 - 88.
2Menczer J, Levy T, Piura B, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol, 2005,97( 1 ) :166-170.
3McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer, 2002, 12(6) :687-690.
4Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol, 2004, 93( 1 ):204-208.
5Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase Ⅲ trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage Ⅰ-Ⅳ carcinosarcoma (CS) of the uterus. Gynecol Oncol, 2007, 107(2) :177-185.
6Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys, 2004, 58(3) :786-796.
7Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage Ⅰ or Ⅱ carcinosarcomas ( mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 2005, 96(3):630-634.
8Homesley HD, Filiaci V, Markman M, et al. Phase Ⅲ trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol, 2007, 25 ( 5 ): 526-531.
9Cimbaluk D, Rotmensch J, Scudiere J, et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol, 2007, 105 ( 1 ) : 138- 144.
10Caudell JJ, Deavers MT, Slomovitz BM, et al. Imatinib mesylate (gleevec)-targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol, 2005, 13(2):167-170.
2Aghajanian C,Sill MW,Secord AA,et a/.Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a gynecologic oncology group study[J].Gyneco| Oncol, 2012,126(3) : 424-427.
3Kowalewska M,Danska-Bidzinska A,Bakula-Zalewska E, et aLIdentification of suitable reference genes for gene expression measurement in uterine sarcoma and carcinosarcoma tumors [J].Clin Biochem, 2012,45 (4 -5 ) : 368-371.
